Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase III Trial Comparing Nanoparticle-based Paclitaxel With Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Patients With Early Breast Cancer (GeparSepto)

NCT01583426 is registered in ClinicalTrials.gov with GBG Forschungs GmbH as lead sponsor.

NCT NCT01583426
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01583426 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase III Trial Comparing Nanoparticle-based Paclitaxel With Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Patients With Early Breast Cancer (GeparSepto)
Lead sponsor
GBG Forschungs GmbH
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2012
Completion date
December 31, 2018
Enrollment
1,229 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer female nos, her-2 positive breast cancer, inflammatory breast cancer, inflammatory breast cancer stage iv, invasive ductal breast cancer, mucinous breast cancer stage ii, tubular breast cancer stage ii, tubular breast cancer stage iii